Pamela Samson

Medicine & Life Sciences

1. Non-Small Cell Lung Carcinoma 100%
2. Radiotherapy 55%
3. Survival 50%
4. Radiosurgery 41%
5. Esophageal Neoplasms 35%
6. Esophagectomy 33%
7. Lung Neoplasms 26%
8. Neoplasms 22%
9. Drug Therapy 21%
10. Therapeutics 19%
11. Adjuvant Chemotherapy 18%
12. Databases 18%
13. Ventricular Tachycardia 16%
14. Confidence Intervals 16%
15. Odds Ratio 12%
16. Chemoradiotherapy 11%
17. Cone-Beam Computed Tomography 11%
18. Mortality 11%
19. Organs at Risk 11%
20. Comorbidity 11%
21. Shared Decision Making 11%
22. Glioblastoma 10%
23. Veterans Health 10%
24. United States Department of Veterans Affairs 9%
25. Neoadjuvant Therapy 9%
26. Workflow 9%
27. Thorax 9%
28. Cost-Benefit Analysis 9%
29. durvalumab 9%
30. Radiation 8%
31. Veterans 8%
32. Adenocarcinoma 8%
33. Muscle Neoplasms 8%
34. Elderly 8%
35. Video-Assisted Thoracic Surgery 7%
36. Recurrence 7%
37. Histology 7%
38. Cardiotoxicity 7%
39. Proton Therapy 7%
40. Carcinoma 7%
41. Respiration 6%
42. Guidelines 6%
43. Rectal Neoplasms 6%
44. Tomography 6%
45. Lymphopenia 6%
46. Aged, 80 and over 6%
47. Radiation Oncology 6%
48. Induction Chemotherapy 6%
49. Biological Therapy 6%
50. Progression-Free Survival 6%